Fusun Can1, Ozlem Kurt Azap2, Ceren Seref1, Pelin Ispir1, Hande Arslan2, Onder Ergonul3. 1. Department of Medical Microbiology, Koç University, School of Medicine, Istanbul. 2. Department of Infectious Diseases, Baskent University, School of Medicine, Ankara. 3. Department of Infectious Diseases, Koç University, School of Medicine, Istanbul, Turkey.
Abstract
BACKGROUND: We described the clinical predictive role of emerging Escherichia coli O25b/sequence type 131 (ST131) in treatment failure of urinary tract infection. METHODS: In this prospective observational cohort study, the outpatients with acute cystitis with isolation of E. coli in their urine cultures were assessed. All the patients were followed up for clinical cure after 10 days of treatment. Detection of the E. coli O25:H4/ST131 clone was performed by multiplex polymerase chain reaction (PCR) for phylogroup typing and using PCR with primers for O25b rfb and allele 3 of the pabB gene. RESULTS: In a cohort of patients with diagnosis of acute urinary cystitis, 294 patients whose urine cultures were positive with a growth of >10(4) colony-forming units/mL of E. coli were included in the study. In empiric therapy, ciprofloxacin was the first choice of drug (27%), followed by phosphomycin (23%), trimethoprim-sulfamethoxazole (TMP-SMX) (9%), and cefuroxime (7%). The resistance rate was 39% against ciprofloxacin, 44% against TMP-SMX, and 25% against cefuroxime. Thirty-five of 294 (12%) isolates were typed under the O25/ST131 clone. The clinical cure rate was 85% after the treatment. In multivariate analysis, detection of the O25/ST131 clone (odds ratio [OR], 4; 95% confidence interval [CI], 1.51-10.93; P = .005) and diabetes mellitus (OR, 2.1; 95% CI, .99-4.79; P = .05) were found to be significant risk factors for the treatment failure. In another multivariate analysis performed among quinolone-resistant isolates, treatment failure was 3 times more common among the patients who were infected with ST131 E. coli (OR, 3; 95% CI, 1.27-7.4; P = .012). CONCLUSIONS: In urinary tract infections, the E. coli ST131 clone seems to be a consistent predictor of treatment failure.
BACKGROUND: We described the clinical predictive role of emerging Escherichia coli O25b/sequence type 131 (ST131) in treatment failure of urinary tract infection. METHODS: In this prospective observational cohort study, the outpatients with acute cystitis with isolation of E. coli in their urine cultures were assessed. All the patients were followed up for clinical cure after 10 days of treatment. Detection of the E. coli O25:H4/ST131 clone was performed by multiplex polymerase chain reaction (PCR) for phylogroup typing and using PCR with primers for O25b rfb and allele 3 of the pabB gene. RESULTS: In a cohort of patients with diagnosis of acute urinary cystitis, 294 patients whose urine cultures were positive with a growth of >10(4) colony-forming units/mL of E. coli were included in the study. In empiric therapy, ciprofloxacin was the first choice of drug (27%), followed by phosphomycin (23%), trimethoprim-sulfamethoxazole (TMP-SMX) (9%), and cefuroxime (7%). The resistance rate was 39% against ciprofloxacin, 44% against TMP-SMX, and 25% against cefuroxime. Thirty-five of 294 (12%) isolates were typed under the O25/ST131 clone. The clinical cure rate was 85% after the treatment. In multivariate analysis, detection of the O25/ST131 clone (odds ratio [OR], 4; 95% confidence interval [CI], 1.51-10.93; P = .005) and diabetes mellitus (OR, 2.1; 95% CI, .99-4.79; P = .05) were found to be significant risk factors for the treatment failure. In another multivariate analysis performed among quinolone-resistant isolates, treatment failure was 3 times more common among the patients who were infected with ST131E. coli (OR, 3; 95% CI, 1.27-7.4; P = .012). CONCLUSIONS: In urinary tract infections, the E. coli ST131 clone seems to be a consistent predictor of treatment failure.
Authors: James R Johnson; Paul Thuras; Brian D Johnston; Scott J Weissman; Ajit P Limaye; Kim Riddell; Delia Scholes; Veronika Tchesnokova; Evgeni Sokurenko Journal: Clin Infect Dis Date: 2016-03-29 Impact factor: 9.079
Authors: Eliana S Armstrong; Janelle A Mikulca; Daniel J Cloutier; Caleb A Bliss; Judith N Steenbergen Journal: BMC Infect Dis Date: 2016-11-25 Impact factor: 3.090
Authors: Ana Carolina C Campos; Nathália L Andrade; Mithila Ferdous; Monika A Chlebowicz; Carla C Santos; Julio C D Correal; Jerome R Lo Ten Foe; Ana Cláudia P Rosa; Paulo V Damasco; Alex W Friedrich; John W A Rossen Journal: Front Microbiol Date: 2018-02-16 Impact factor: 5.640
Authors: Rodrigo E Mendes; Mariana Castanheira; Leanne Gasink; Gregory G Stone; Wright W Nichols; Robert K Flamm; Ronald N Jones Journal: Antimicrob Agents Chemother Date: 2015-12-14 Impact factor: 5.191